Ishaq A. Viringipurampeer
University of British Columbia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ishaq A. Viringipurampeer.
Cell Death & Differentiation | 2014
Ishaq A. Viringipurampeer; Xianghong Shan; Kevin Gregory-Evans; J P Zhang; Zeinabsadat Mohammadi; Cheryl Y. Gregory-Evans
Achromatopsia is a progressive autosomal recessive retinal disease characterized by early loss of cone photoreceptors and later rod photoreceptor loss. In most cases, mutations have been identified in CNGA3, CNGB3, GNAT2, PDE6C or PDE6H genes. Owing to this genetic heterogeneity, mutation-independent therapeutic schemes aimed at preventing cone cell death are very attractive treatment strategies. In pde6cw59 mutant zebrafish, cone photoreceptors expressed high levels of receptor-interacting protein kinase 1 (RIP1) and receptor-interacting protein kinase 3 (RIP3) kinases, key regulators of necroptotic cell death. In contrast, rod photoreceptor cells were alternatively immunopositive for caspase-3 indicating activation of caspase-dependent apoptosis in these cells. Morpholino gene knockdown of rip3 in pde6cw59 embryos rescued the dying cone photoreceptors by inhibiting the formation of reactive oxygen species and by inhibiting second-order neuron remodelling in the inner retina. In rip3 morphant larvae, visual function was restored in the cones by upregulation of the rod phosphodiesterase genes (pde6a and pde6b), compensating for the lack of cone pde6c suggesting that cones are able to adapt to their local environment. Furthermore, we demonstrated through pharmacological inhibition of RIP1 and RIP3 activity that cone cell death was also delayed. Collectively, these results demonstrate that the underlying mechanism of cone cell death in the pde6cw59 mutant retina is through necroptosis, whereas rod photoreceptor bystander death occurs through a caspase-dependent mechanism. This suggests that targeting the RIP kinase signalling pathway could be an effective therapeutic intervention in retinal degeneration patients. As bystander cell death is an important feature of many retinal diseases, combinatorial approaches targeting different cell death pathways may evolve as an important general principle in treatment.
Human Molecular Genetics | 2012
Ishaq A. Viringipurampeer; Todd Ferreira; Shannon DeMaria; Jookyung J. Yoon; Xianghong Shan; Mariya Moosajee; Kevin Gregory-Evans; John Ngai; Cheryl Y. Gregory-Evans
Tissue fusion is an essential morphogenetic mechanism in development, playing a fundamental role in developing neural tube, palate and the optic fissure. Disruption of genes associated with the tissue fusion can lead to congenital malformations, such as spina bifida, cleft lip/palate and ocular coloboma. For instance, the Pax2 transcription factor is required for optic fissure closure, although the mechanism of Pax2 action leading to tissue fusion remains elusive. This lack of information defining how transcription factors drive tissue morphogenesis at the cellular level is hampering new treatments options. Through loss- and gain-of-function analysis, we now establish that pax2 in combination with vax2 directly regulate the fas-associated death domain (fadd) gene. In the presence of fadd, cell proliferation is restricted in the developing eye through a caspase-dependent pathway. However, the loss of fadd results in a proliferation defect and concomitant activation of the necroptosis pathway through RIP1/RIP3 activity, leading to an abnormal open fissure. Inhibition of RIP1 with the small molecule drug necrostatin-1 rescues the pax2 eye fusion defect, thereby overcoming the underlying genetic defect. Thus, fadd has an essential physiological function in protecting the developing optic fissure neuroepithelium from RIP3-dependent necroptosis. This study demonstrates the molecular hierarchies that regulate a cellular switch between proliferation and the apoptotic and necroptotic cell death pathways, which in combination drive tissue morphogenesis. Furthermore, our data suggest that future therapeutic strategies may be based on small molecule drugs that can bypass the gene defects causing common congenital tissue fusion defects.
International Journal of Inflammation | 2013
Ishaq A. Viringipurampeer; Abu E. Bashar; Cheryl Y. Gregory-Evans; Orson L. Moritz; Kevin Gregory-Evans
Genetic retinal diseases such as age-related macular degeneration and monogenic diseases such as retinitis pigmentosa account for some of the commonest causes of blindness in the developed world. Diverse genetic abnormalities and environmental causes have been implicated in triggering multiple pathological mechanisms such as oxidative stress, lipofuscin deposits, neovascularisation, and programmed cell death. In recent years, inflammation has also been highlighted although whether inflammatory mediators play a central role in pathogenesis or a more minor secondary role has yet to be established. Despite this, numerous interventional studies, particularly targeting the complement system, are underway with the promise of novel therapeutic strategies for these important blinding conditions.
Molecular Neurobiology | 2018
Ishaq A. Viringipurampeer; Cheryl Y. Gregory-Evans; Andrew Metcalfe; Emran Bashar; Orson L. Moritz; Kevin Gregory-Evans
Retinitis pigmentosa (RP) is a group of inherited neurological disorders characterized by rod photoreceptor cell death, followed by secondary cone cell death leading to progressive blindness. Currently, there are no viable treatment options for RP. Due to incomplete knowledge of the molecular signaling pathways associated with RP pathogenesis, designing therapeutic strategies remains a challenge. In particular, preventing secondary cone photoreceptor cell loss is a key goal in designing potential therapies. In this study, we identified the main drivers of rod cell death and secondary cone loss in the transgenic S334ter rhodopsin rat model, tested the efficacy of specific cell death inhibitors on retinal function, and compared the effect of combining drugs to target multiple pathways in the S334ter and P23H rhodopsin rat models. The primary driver of early rod cell death in the S334ter model was a caspase-dependent process, whereas cone cell death occurred though RIP3-dependent necroptosis. In comparison, rod cell death in the P23H model was via necroptotic signaling, whereas cone cell loss occurred through inflammasome activation. Combination therapy of four drugs worked better than the individual drugs in the P23H model but not in the S334ter model. These differences imply that treatment modalities need to be tailored for each genotype. Taken together, our data demonstrate that rationally designed genotype-specific drug combinations will be an important requisite to effectively target primary rod cell loss and more importantly secondary cone survival.
Journal of Tissue Engineering and Regenerative Medicine | 2017
Anat Yanai; Ishaq A. Viringipurampeer; Emran Bashar; Kevin Gregory-Evans
Cell therapy, to replace lost tissue, is a promising approach for the treatment of various neurodegenerative diseases. Many studies suggest, however, that the percentage of transplanted cells that survive and undergo functional integration remains low as a result of immune rejection, suboptimal precursor cell type, trauma during cell transplantation, toxic compounds released by dying tissues or nutritional deficiencies. We recently developed an ex vivo system to facilitate identification of factors contributing to the death of transplanted neuronal (photoreceptor) cells and compounds that block these toxic effects. In this system, photoreceptor precursor cells (PPCs) are sandwiched between a neurosensory retinal explant and retinal pigment epithelium derived from human embryonic stem cells. Explant medium was collected to identify toxic components and PPC survival was assessed by flow cytometry. We also assessed the potential for AAGP™, a cryopreservative molecule, to improve PPC survival. We identified elevated prostaglandin E2 (PGE2) in the explant medium and demonstrated that AAGP™ reduced PGE2 levels by 2.6‐fold. A pro‐inflammatory stress assay suggested that this may result from AAGP™ inhibition of cyclo‐oxygenase‐2 (COX‐2) expression. We confirmed that PGE2 reduced the viability of cultured PPCs by 44% and found that the survival rate of PPCs pretreated with AAGP™ was 2.8‐fold higher than in untreated PPCs. These data suggest that PGE2 release from necrotic tissue may be one factor that reduces the survival of transplanted precursor cells and that the pro‐survival molecule AAGP™ may improve long‐term transplanted cell viability. Copyright
Tissue Engineering Part C-methods | 2013
Anat Yanai; Christopher Laver; Aaron W. Joe; Ishaq A. Viringipurampeer; Xia Wang; Cheryl Y. Gregory-Evans; Kevin Gregory-Evans
Molecular Vision | 2016
Abu E. Bashar; Andrew Metcalfe; Ishaq A. Viringipurampeer; Anat Yanai; Cheryl Y. Gregory-Evans; Kevin Gregory-Evans
Investigative Ophthalmology & Visual Science | 2015
Cheryl Y. Gregory-Evans; Ishaq A. Viringipurampeer; Andrew Metcalfe; Emran Bashar; Zeinabsadat Mohammadi; Orson L. Moritz; Kevin Gregory-Evans
Investigative Ophthalmology & Visual Science | 2015
Zeinabsadat Mohammadi; Ishaq A. Viringipurampeer; Kevin Gregory-Evans; Cheryl Y. Gregory-Evans
Investigative Ophthalmology & Visual Science | 2013
Ishaq A. Viringipurampeer; Zeinabsadat Mohammadi; Xianghong Shan; Kevin Gregory-Evans; Cheryl Y. Gregory-Evans